Hopkins, A.L.

ORCID iD
orcid.org/0000-0003-1977-018X
  • Keywords
  • Show details Hide details
Informatics, Drug Discovery, Biophyiscs, Polypharmacology, Automated Drug Design

Sources:
Hopkins, A.L. (2013-12-04)

  • Other IDs
  • Show details Hide details
ResearcherID: H-5138-2011

Sources:
Clarivate Analytics (2013-10-31)

Biography

Professor Hopkins is Chair of Medicinal Informatics and SULSA Research Professor of Translational Biology, in the College of Life Sciences, University of Dundee, where he is also the Director of SULSA – the Scottish Universities Life Sciences Alliance. The Hopkins Laboratory is focused on developing new informatics and experimental methods for drug discovery, and applying these to the discovery and optimisation of novel leads. His research focuses on developing novel computational methods for automating drug design and chemogenomics. Experimentally, his lab is interested in advancing biosensor based screening, with particular interesting in developing fragment-based drug discovery for GPCRs. In 1993 Prof. Hopkins won a British Steel scholarship to attend University of Manchester graduating with a First Class Honours in Chemistry. Following a spell in the steel industry, Professor Hopkins undertook a doctorate in molecular biophysics under at the University of Oxford. Directly from Oxford he joined Pfizer, in 1998, where he established various new functions for the company including the Target Analysis Group, Indications Discovery and Knowledge Discovery. Prof Hopkins is a Fellow of the both the Royal Society of Chemistry and the Society of Biology. He has won several awards including the Royal Society of Chemistry’s Capps Green Zomaya medal (2008); Corwin Hansch Award (2007); Pfizer Team Achievement Award (2004); Pfizer Achievement Award (2002); Pfizer Leadership Award (2002). He has over 50 scientific publications and patents, including two papers with over 1000 citations and fourteen papers with over 100 citations. Prof Hopkins is the co-founder of Kinetic Discovery Ltd, a company offering biosensor-screening services to the pharmaceutical industry. In 2012 he founded ex scientia Ltd to apply automated design methods to the challenge of improving drug discovery productivity.
No publications added yet